U.S. FDA approves Rigel Pharma's leukemia treatment
01/12/2022 22:15
Dec 1 (Reuters) - Rigel Pharmaceuticals RIGL.O said on Thursday the U.S. Food and Drug Administration has approved its drug for the treatment of patients with a type of leukemia. (Reporting by Leroy Leo in Bengaluru; Editing by Maju Samuel) ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)